



Marine Natural Products with Antiprotozoal Activity

Guest Editors:

Dr. Ana R. Díaz-Marrero

Instituto de Productos Naturales
y Agrobiología (IPNA), Consejo
Superior de Investigaciones
Científicas (CSIC), Avenida
Astrofísico Francisco Sánchez 3,
38206 La Laguna, Tenerife, Spain

Dr. Jacob Lorenzo-Morales

Departamento de Obstetricia,
Ginecología, Pediatría, Medicina
Preventiva y Salud Pública,
Toxicología, Medicina Legal y
Forense y Parasitología,
Universidad de La Laguna (ULL),
Avda. Astrofísico F. Sánchez, 2,
38206 La Laguna, Tenerife, Spain

Deadline for manuscript
submissions:

closed (30 December 2019)

Message from the Guest Editors

Infections caused by protozoan parasites are responsible for a large number of severe and widespread diseases which include malaria, leishmaniasis, Chagas disease or human African trypanosomiasis, among others. They mostly affect rural and poor urban areas of tropical and subtropical regions causing a considerable morbidity and mortality worldwide. Current drug treatments are ineffective due to drug resistance and toxicity in addition to their high cost and prolonged treatments. The search for new lead compounds with novel mechanisms of action for development of more effective treatments with fewer side effects represents a crucial challenge.

The marine environment is plenty of microorganisms, algae and marine invertebrates which are a rich potential source of novel molecules with high structural diversity and “drug-like” properties. As Guest Editors of this Special Issue of Marine Drugs, We encourage scientists working in any field involving marine natural products with antiprotozoal activities to submit recent research that may lead to significant advances.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

Contact Us

Marine Drugs Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)